Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/10/2014 | 02:01pm CET

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck's chairman and chief executive officer, is scheduled to present at the 32ndAnnual J.P. Morgan Healthcare Conference in San Francisco on January 13 at 4:00 p.m. PST (7:00 p.m. EST). Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media Contact:
Kelley Dougherty, 908-423-4291
or
Investor Contact:
Carol Ferguson, 908-423-4465


© Business Wire 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
11/17 MERCK AND : ACC, John L. Weinberg Center for Corporate Governance Interview Merc..
11/16 MERCK AND : StayWells Krames On FHIR App Listed in App Orchard
11/16 BERGENBIO : to present at Jefferies 2017 London Healthcare Conference
11/16 BERGENBIO : to present at Jefferies 2017 London Healthcare Conferenc
11/16 MERCK AND : Pro Bono Partnership Celebrated 20th Anniversary with Record-Breakin..
11/15DJMERCK AND : Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases -- Upda..
11/15 MERCK AND : StayWell's Krames On FHIR® App Listed in App Orchard
11/15 Bayer hires new blood to stem 'Amazon effect' in consumer health
11/15 MERCK AND : Receives Positive CHMP Opinion for PREVYMIS in the European Union
11/14 MERCK : Announces Final Results of Any and All Tender Offers
More news
News from SeekingAlpha
08:47a Merck under pressure premarket on positive data Tecentriq data in lung cancer..
02:23a Tracking Tweedy Browne Portfolio - Q3 2017 Update
11/17 BIOTECH FORUM DAILY DIGEST : What Heron's FDA Approval Means
11/17 DIVIDEND CHALLENGERS (AND NEAR-CHALL : 58 Increases Expected By The End Of Janua..
11/16 GREEN DOT PORTFOLIO : Part 2 - Inside The Portfolio
Financials ($)
Sales 2017 40 238 M
EBIT 2017 13 727 M
Net income 2017 5 247 M
Debt 2017 12 094 M
Yield 2017 3,42%
P/E ratio 2017 26,68
P/E ratio 2018 17,24
EV / Sales 2017 4,04x
EV / Sales 2018 3,96x
Capitalization 151 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 65,6 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-6.23%150 550
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
AMGEN16.27%123 405